If you're an individual retail investor searching for healthcare stocks you can buy and hold for at least 20 years, here are ...

Caribou Biosciences Inc. (NASDAQ:CRBU) shares skyrocketed 100% on Monday after the company released promising Phase 1 ...

Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.

The announcement comes just weeks after President Trump publicly spread debunked claims that Tylenol consumption is linked to autism.

Kimberly-Clark Corp. will acquire Tylenol maker Kenvue Inc. in a cash and stock deal valued at almost $49 billion the two companies announced Nov. 3.

Kleenex maker Kimberly-Clark will buy Kenvue at a 46% premium, tanking its own stock by 13%. Synergies promise a decent ...

Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell ...